Study: Stereotactic Radiosurgery Provides Improved Survival Rates for Metastatic Brain Tumor in Patients Under 50

According to a study recently published in the scientific journal of the American Society for Radiation Oncology (ASTRO), cancer patients with limited brain metastases who are under the age of 50 could benefit from receiving stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT).

The study analyzed patient data from the three largest randomized clinical trials of SRS and WBRT conducted to date, and found that for patients under 50 who received SRS alone, survival was improved by 13 percent when compared to those patients under the age of 50 who received both SRS and WBRT.

“We expected to see a survival advantage favoring combined therapy of SRS and WBRT. However, these data clearly demonstrate the benefit of SRS alone to improve survival for our younger patients with limited brain metastases,” explained lead author Arjun Sahgal, MD.

At Illinois CyberKnife, metastatic brain tumors are treated with SRS using advanced CyberKnife® technology. Contact us at (847) 723-0100 for more information on our treatment process or to schedule a consultation to discuss whether you may be a candidate for CyberKnife treatment.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.